Company: ISRG
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001035267-25-000098
Chunk: 98

Company: INTUITIVE SURGICAL INC
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 98
---
 are a non-binding shareholder vote is required for unreasonably rich golden parachutes.

This proposal places no limit on long-term equity pay or any other type pay. This proposal thus has no impact on the ability to attract executive talent and does not discourage the use of long-term equity pay because it places no limit on golden parachutes. It simply requires that overly rich golden parachutes be subject to a non-binding shareholder vote at a shareholder meeting already scheduled for other matters.

This proposal is relevant because the annual say on executive pay vote does not have a separate section for approving or rejecting golden parachutes.

This proposal topic also received between 51% and 65% support at:

FedEx (FDX)

Spirit AeroSystems (SPR)

Alaska Air (ALK)

AbbVie (ABBV)

Fiserv (FISV)

This proposal is most important at Intuitive Surgical since Intuitive Surgical ranks 7 in regard to executive pay with 10 being the worst possible score.

83

<div align='center'>Please vote yes:

Shareholder Approval Requirement for Excessive Golden Parachutes – Proposal 6</div>

84

### BOARD STATEMENT IN OPPOSITION
The Board of Directors (the “Board”) has carefully considered this proposal, and the Company has engaged in discussion with the proponent to exchange perspectives on this topic. However, for the reasons described below, the Board believes that the proposal is not in the best interests of the Company and its stockholders and unanimously recommends a vote AGAINST this proposal.

The severance policy requested by the proposal would substantially diminish the Company’s competitive recruiting and limit our ability to retain highly qualified executive talent compared to our peer companies.

The primary objective of our executive compensation program is to attract and retain a passionate team of executives who will provide leadership to advance our Company’s work to drive innovation that enables physicians and healthcare providers to improve the quality of and access to minimally invasive care for the patients they serve. This goal is highly aligned with the long-term interests of our stockholders. Our Compensation Committee, a committee of the Board, with the assistance of outside consultants and senior management, carefully designs the Company’s executive compensation program and each compensation element with this objective in mind.

We operate in a challenging and dynamic business environment, and our strong performance to date has been driven in large part by our carefully tailored compensation program. For example, fourth quarter 2024 revenue saw a 25% increase from the fourth quarter of the prior year, exceeding street estimates and contributing to strong stock price return